If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
air conditioning to defined temperature ranges, in the U.S., entities are required to provide plans to reduce their water usage, and China experiences large blackouts and experiments with cloud seeding among other measures, despite experts stating it would be "marginally effective" and possibly exacerbate problems. Several journalists of online newspapers have put these extreme weather events into the context of climate change adaptation (alongside highlighting of the importance of climate change mitigation). 15 August – A study on the food impacts of a nuclear war is published. It finds that even a small-scale conflict between India and Pakistan would decrease global average caloric production by 7%, while a full-scale U.S.-Russia nuclear conflict would result in a 90% loss, killing more than 5 billion people worldwide.
A moderate degree of iron-deficiency anemia affects approximately 610 million people worldwide or 8.8% of the population. It is slightly more common in females (9.9%) than males (7.8%). Up to 15% of children ages 1–3 years have iron deficiency anemia. Mild iron deficiency anemia affects another 375 million. Iron deficiency affects up to 52% of pregnant women worldwide. The prevalence of iron deficiency as a cause of anemia varies among countries; in the groups in which anemia is most common, including young children and a subset of non-pregnant women, iron deficiency accounts for a fraction of anemia cases in these groups (25% and 37%, respectively). Iron deficiency is common in pregnant women. Within the United States, iron-deficiency anemia affects about 2% of adult males, 10.5% of White women, and 20% of African-American and Mexican-American women. A study in 2024 suggests that nearly 1 in 3 Americans may have undiagnosed iron deficiency, which can cause fatigue, brain fog, and concentration problems. The analysis of data from over 8,000 U.S. adults found that 14% had low iron levels, known as absolute iron deficiency; 15% had normal iron levels but their bodies couldn't effectively use the mineral, a condition called functional iron deficiency. A map provides a country-by-country listing of what nutrients are fortified into specified foods. Some of the Sub-Saharan countries shown in the deaths from iron-deficiency anemia map from 2012 are, as of 2018, fortifying foods with iron.
Manchester United defeat Manchester City 2–1 to win the 2024 FA Cup final. 26 May – British event rider Georgie Campbell dies after falling from her horse at the Bicton International Horse Trials in Devon. 27 May 2024 general election: Lucy Allan, outgoing Conservative MP for Telford is suspended from her party for backing Alan Adams, the Reform UK candidate to be her replacement. The RAF temporarily grounds its Spitfire planes following the fatal crash two days earlier. The FBI is reported to be investigating the sale of hundreds of British Museum artefacts to buyers in the United States. 28 May – Diane Abbott is readmitted as a Labour MP, following her suspension the previous year. 30 May 2024 general election: The Parliament elected in 2019 is dissolved. Buckingham Palace confirms that Charles III will attend the 2024 Trooping the Colour ceremony. 31 May – BBC News reports that the Battle of Britain Memorial Flight will not fly as part of D-Day anniversary events following the death of Squadron Leader Mark Long.
==== Granular glands ==== Granular glands can be identified as venomous and often differ in the type of toxin as well as the concentrations of secretions across various orders and species within the amphibians. They are located in clusters differing in concentration depending on amphibian taxa. The toxins can be fatal to most vertebrates or have no effect against others. These glands are alveolar meaning they structurally have little sacs in which venom is produced and held before it is secreted upon defensive behaviors. Structurally, the ducts of the granular gland initially maintain a cylindrical shape. When the ducts mature and fill with fluid, the base of the ducts become swollen due to the pressure from the inside. This causes the epidermal layer to form a pit like opening on the surface of the duct in which the inner fluid will be secreted in an upwards fashion. The intercalary region of granular glands is more developed and mature in comparison with mucous glands. This region resides as a ring of cells surrounding the basal portion of the duct which are argued to have an ectodermal muscular nature due to their influence over the lumen (space inside the tube) of the duct with dilation and constriction functions during secretions. The cells are found radially around the duct and provide a distinct attachment site for muscle fibers around the gland's body. The gland alveolus is a sac that is divided into three specific regions/layers.
Sources: en.wikipedia.org
== Trivial names of some resorcinolic lipids == olivetol persoonol grevillol ardisinol I ardisinol II adipostatin A adipostatin B bilobol hexylresorcinol hydrobilobol cardol rucinol irisresorcinol panosialin stemphol R-leprosol α-leprosol merulinic acid xenognosin
=== Remodeling === There are progenitor cells in the periodontal ligament that can differentiate into osteoblasts for the physiological maintenance of alveolar bone and, most likely, for its repair as well.
patent, Preparation of a Whey Protein Concentrate, combined pretreatment and ultrafiltration with water injection and cation exchange to produce a low-mineral, acid-soluble whey protein concentrate suitable for beverage formulations. The water-injection step, or diafiltration, adds water during ultrafiltration so that additional lactose, minerals, and other permeable constituents are removed, while retaining the protein. Diafiltration subsequently became an important method for manufacturing higher-protein whey protein concentrates and whey protein isolates. The New Zealand Dairy Board received a non-exclusive, royalty-free license to use the Coca-Cola process with New Zealand whey. The Dairy Board and NZDRI continued investing in whey-protein processing and product development. The work initiated for Coca-Cola generated deep expertise and provided a technological base for developing whey protein concentrates for other applications and markets. In 1982, the industry established the Whey Products Corporation to coordinate whey processing, investment, and marketing across the cooperative dairy sector. This approach enabled New Zealand to become a leading supplier of technically demanding whey-protein products during the 1980s and 1990s. The industry's centralized whey-products operations were later folded back into the Dairy Board, which merged with Kiwi Co-operative Dairies and New Zealand Dairy Group in 2001 to form Fonterra.
Sources: en.wikipedia.org
Shallot is also pickled—called shour (شور) in Persian—along with other vegetables to be served as torshi. In Southeast Asian cuisines, such as those of Indonesia, Vietnam, Thailand, Cambodia, Malaysia, the Philippines, Singapore, and Brunei, both shallots and garlic are often used as elementary spices. Raw shallots can also accompany cucumbers when pickled in mild vinegar solution. They are also often chopped finely, then fried until golden brown, resulting in tiny, crispy shallot chips called bawang goreng (fried shallots) in Indonesian, which can be bought ready-made from groceries and supermarkets. Shallots enhance the flavor of many Southeast Asian dishes, such as fried rice variants. They are also often present in noodle and slaw dishes. Crispy shallot chips are also used in southern Chinese cuisine. In Indonesia, shallots are sometimes pickled and added to several traditional foods; the pickles' sourness is thought to increase the appetite. In the southern Philippines, shallot bulbs and leaves are used to make the popular spicy Maranao condiment called palapa, which is used in the dish piaparan. The tubular green leaves of the plant can also be eaten and are very similar to the leaves of spring onions and chives.
Insulin receptor substrate 4 is a protein that in humans is encoded by the IRS4 gene. IRS4 encodes the insulin receptor substrate 4, a cytoplasmic protein that contains many potential tyrosine and serine/threonine phosphorylation sites. Tyrosine-phosphorylated IRS4 protein has been shown to associate with cytoplasmic signalling molecules that contain SH2 domains. The IRS4 protein is phosphorylated by the insulin receptor tyrosine kinase upon receptor stimulation.
Its inhabitants—referred to as "Wellies"—wear white "Happy Face" masks, which were created to forcefully mold the wearer's cheekbones into a smile, resulting in the wearer permanently smiling. Joy is freely dispensed in pill form and is also laced into the city's water supply. To encourage the drug's consumption, the media is tightly controlled and centers on "Uncle" Jack Worthing, a friendly presenter whose voice and image widely broadcasts government propaganda over the city's televisions and radios. Some Wellies developed immunity to Joy—partly due to ingesting bad batches of the drug—and subsequently became depressed or insane from remembering the Very Bad Thing; these people were then driven out of Wellington Wells and came to be known as "Wastrels". Others who voluntarily refuse their Joy are known as "Downers" and seen as a threat; if caught, Downers are either force-fed Joy, are taken to a Joy Doctor to get a potentially lethal liquid injection of Joy, or are outright killed on the spot. As a result, Wellington Wells has become a dystopian police state on the verge of collapse.
As the price of bitcoin rose to $44,000 in December 2023, Bukele announced that El Salvador's investment into bitcoin had broken even. In March 2024, he stated that El Salvador had made a 50-percent profit from bitcoin. Bukele mocked news-media outlets on Twitter, saying that there were "literally thousands of articles" about El Salvador's bitcoin losses and the same outlets were now "totally silent". By 19 January 2025, the Salvadoran government had 6,043 bitcoins worth $611.2 million. In November 2021, Bukele announced that he planned to build Bitcoin City in the southeastern region of La Unión at the base of the Conchagua volcano. The city would use geothermal energy to power bitcoin mining. Ricardo Navarro, head of the Salvadoran Center of Appropriate Technology, criticized the plan, adding that it would result in an "environmental disaster". Bukele published images of models of Bitcoin City and its planned airport on Twitter in May 2022, saying that the city would have "no income tax, zero property tax, no procurement tax, zero city tax, and zero CO2 emissions". In December 2023, the Legislative Assembly passed a law that allowed individuals to purchase Salvadoran citizenship by donating bitcoins to El Salvador. On 18 December 2024, the International Monetary Fund (IMF) agreed to give El Salvador a $1.4 billion loan in exchange for the Salvadoran government making some concessions from the Bitcoin Law.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.